3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
2
Solid Tumors
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Metastatic Castration-Resistant Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
inavolisib
×
Clear all
NCT05708235
2026-03-05
MiRaDoR
MedSIR
Phase 2
Recruiting
976 enrolled